Drug intelligence / Profile preview

ZAX.1400.EC.02

Development stage: Unknown
Modality: Small Molecules
Administration: Topical

Overview

ZAX.1400.EC.02 is a topical cream-based drug under clinical investigation for its anti-inflammatory effects, particularly in the treatment of skin inflammation conditions such as eczema and atopic dermatitis. It is applied twice daily over a 21-day period with patient evaluation extending up to 42 days in clinical trials. The drug's mechanism of action involves anti-inflammatory activity, although specific molecular targets or pathways have not been detailed publicly.

Other names: ZAX.1400.EC.02

Beyond the preview

Go deeper on ZAX.1400.EC.02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZAX.1400.EC.02.

Explore the full profile